Sentum Scientific

Sentum Scientific is a preclinical-stage biotechnology company dedicated to advancing the field of cellular senescence to treat age-related diseases and improve healthspan. The company utilizes a proprietary discovery platform to identify and target senescent cells, which accumulate with age and contribute to chronic inflammation and tissue dysfunction. Their therapeutic approach focuses on developing senolytics to selectively induce apoptosis in these cells and senomorphics to modulate the senescence-associated secretory phenotype (SASP). Sentum's current pipeline targets indications such as pulmonary fibrosis and the reduction of side effects associated with chemotherapy. Founded as a spin-off from the University of Groningen, the company is backed by prominent longevity-focused investors and aims to translate fundamental aging research into clinical applications.